O n Monday, Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to ...

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for ORIC Pharmaceuticals in a report ...

Cantor Fitzgerald notes that the firm discovered ... the high-level news commentary “sounds very positive” for mevrometostat and Oric Pharmaceuticals (ORIC). The firm has an Overweight ...

ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report) is expected to post its quarterly earnings results before the market ...

In a report issued on February 5, Cantor Fitzgerald also maintained a Buy rating on the stock with a $206.00 price target. ORIC Pharmaceuticals NewsMORE Related Stocks ...

US Commerce Secretary Howard Lutnick named his two eldest sons and three company deputies to run the core of his business group after his Senate confirmation Tuesday and resignation from Cantor ...

WASHINGTON (Reuters) -The U.S. Senate voted on Tuesday 51-45 to confirm President Donald Trump's nominee Howard Lutnick, the billionaire chairman and CEO of Wall Street firm Cantor Fitzgerald ...

The Central Bank has fined the Irish unit of US investment group Cantor Fitzgerald €452,790 for failing to report suspicious transactions that may have indicated market abuse. Between March 2017 ...

On Monday, Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to ...